What does Edgewise Therapeutics do today?
Edgewise Therapeutics, Inc. is a Nasdaq-listed clinical-stage biopharmaceutical company developing small-molecule medicines that modulate muscle proteins. Its identity changed in July 2026: after selling sevasemten to Servier, Edgewise became a cardiovascular-focused developer led by EDG-7500. The company’s investor overview now emphasizes a pipeline aimed at serious cardiovascular diseases rather than a mixed cardiac-and-skeletal-muscle portfolio.
Which programs define the new pipeline?
| Program | Target use | Stage in July 2026 | Strategic role |
|---|---|---|---|
| EDG-7500 | Obstructive and nonobstructive hypertrophic cardiomyopathy | Phase 2 data reported; Phase 3 planning | Primary clinical and valuation driver |
| EDG-15400 | Heart failure, including HFpEF development potential | Phase 1 | Second clinical asset and platform validation |
| EDG-003 | Cardiometabolic disease | Discovery/preclinical | Longer-duration option value |
The official pipeline page frames Edgewise as a concentrated R&D portfolio. EDG-7500 is closest to pivotal development, EDG-15400 broadens the cardiac-sarcomere thesis, and EDG-003 remains economically speculative.
Why does the company matter in cardiovascular drug development?
Edgewise is testing a different therapeutic profile from conventional cardiac myosin inhibitors. Management describes EDG-7500 as a selective cardiac sarcomere modulator intended to slow early contraction and improve relaxation while preserving systolic function. The proposition is important but not yet a commercial moat: controlled, adequately powered trials must reproduce the preliminary results.
How does Edgewise make money without an approved product?
Edgewise reported no product revenue through March 31, 2026. Historically, it raised equity, funded discovery and trials, and retained future economics. The Servier transaction added a second model: monetize a program before approval through upfront cash and contingent milestones, then redeploy capital toward retained assets. This is portfolio financing, not recurring revenue.
What are the current economic streams?
The large investment portfolio generated $5.1 million in the quarter ended March 31, 2026, partially offsetting operating losses.
The transaction delivered $1.55 billion upfront at closing, with up to $1.10 billion of additional milestones that remain contingent.
EDG-7500 and the other cardiovascular programs could generate sales or partnership economics only after further development and, where required, regulatory approval.
Why is R&D spending the key operating input?
For a pre-revenue biotechnology company, research spending resembles inventory creation and growth capital, although it is largely expensed immediately. Edgewise’s 2025 Form 10-K reported $151.4 million of R&D expense and $40.0 million of general and administrative expense. Of 146 employees at year-end 2025, 114 worked in research, product development, or clinical activities. The model converts cash into data, regulatory packages, manufacturing readiness, and intellectual property—not near-term gross profit.
How did the Servier transaction change Edgewise’s strategy?
On July 10, 2026, Edgewise completed the sale of sevasemten and related assets to Servier, removing a major development obligation while adding substantial liquidity. The June 1 transaction filing established the terms, and the July 13 completion filing confirmed closing.
What did Edgewise sell, and what did it retain?
| Element | Transferred or retained | Economic implication |
|---|---|---|
| Sevasemten program | Transferred to Servier | Edgewise no longer bears the core future development and commercialization burden. |
| Upfront payment | $1.55 billion cash received at closing | Materially extends funding capacity for the cardiovascular portfolio. |
| Milestones | Up to $1.10 billion retained as contingent rights | Adds asymmetric upside but should not be treated as cash until earned. |
| EDG-7500, EDG-15400, EDG-003 | Retained by Edgewise | Concentrates operating risk and strategic attention on cardiovascular disease. |
| Transition services | Edgewise supports Servier for at least an initial 18-month period | Creates temporary operational complexity, with reimbursed service arrangements. |
What does the pro forma accounting reveal?
The July 16 pro forma financial statements estimated a $1.488 billion pre-tax gain and a $1.262 billion after-tax gain, assuming the transaction had occurred on March 31, 2026. They also included $50.0 million of estimated transaction costs and a $225.9 million income-tax payable. These estimates are not recurring earnings. The filing also showed Q1 2026 continuing-operation R&D of $26.7 million and operating expense of $36.6 million after eliminating direct sevasemten costs.
What does the latest reported financial period show?
The latest conventional reporting period, Q1 2026, predates the Servier closing. Edgewise remained pre-revenue and loss-making, with higher clinical investment than a year earlier. The Q1 2026 Form 10-Q therefore provides the cleanest historical operating view, while the transaction pro forma provides the better current liquidity view.
How did Q1 2026 compare with Q1 2025?
| Metric | Q1 2026 | Q1 2025 | Interpretation |
|---|---|---|---|
| Revenue | $0.0M | $0.0M | The company had no approved commercial product. |
| R&D expense | $42.7M | $36.8M | Higher clinical and personnel activity increased spending 16.0%. |
| G&A expense | $11.5M | $9.2M | Corporate infrastructure and stock compensation remained material. |
| Interest income | $5.1M | $5.2M | Investment income cushioned, but did not offset, operating losses. |
| Net loss | $49.0M | $40.8M | Loss widened as operating expenses increased. |
| Diluted loss per share | $(0.46) | $(0.43) | Per-share loss reflects both spending and the larger share base. |
What does the expense mix say about execution?
The sale lowers the starting expense base, not necessarily the future run rate. Phase 3, manufacturing, regulatory work, and EDG-15400 can lift spending. The key question is whether current cash can fund decisive readouts without near-term external capital.
Why is EDG-7500 now the central value driver?
EDG-7500 is the only retained asset with reported Phase 2 patient data and a stated Phase 3 path. In June 2026, Edgewise reported 12-week open-label CIRRUS-HCM Part D results from 53 patients: 20 with obstructive HCM and 33 with nonobstructive HCM. The company said more than 700 echocardiograms showed no observed relationship between drug exposure and systolic measures, and no left-ventricular ejection fraction reductions below 50%. The observations support the intended profile but cannot establish comparative efficacy or long-term safety.
What did the 12-week CIRRUS-HCM data show?
| Measure | oHCM cohort | nHCM cohort | Research interpretation |
|---|---|---|---|
| Patients completing 12 weeks | 20 | 33 | Small cohorts make replication in Phase 3 essential. |
| Mean KCCQ-OSS change | +24 points | +13 points | Patient-reported health status improved in both cohorts. |
| Mean e’ lateral change | Approximately +20% | +37% | Supports the hypothesis of improved diastolic relaxation. |
| E/e’ change in preliminary high-frame-rate substudy | −5.3 points | −6.1 points | A lower ratio may indicate improved filling pressure, but the substudy remains exploratory. |
| New-onset atrial fibrillation events | 2 patients, or 3.8%; both assessed as unrelated by investigators | Safety surveillance remains important in larger and longer studies. | |
What must Phase 3 prove?
A registrational program must convert biomarker, imaging, functional, and patient-reported signals into prespecified endpoints with acceptable safety. Key details include sample size, control arm, duration, dose, endpoint, enrollment, discontinuations, and coverage of oHCM and nHCM. Edgewise’s official presentations page is the most relevant place to track updated trial design and data disclosures.
Which turning points explain Edgewise’s current position?
Edgewise’s history is best understood as a sequence of financing, platform validation, clinical progression, and portfolio concentration decisions. Each event changed either the company’s scientific credibility, funding runway, or risk distribution.
How did a muscle-biology platform become a focused cardiovascular company?
-
2017Operations began around a precision-medicine platform targeting muscle proteins, establishing the discovery engine behind later cardiac and skeletal-muscle programs.
-
2021The initial public offering created access to public equity capital, enabling larger clinical programs while introducing shareholder dilution as a funding tool.
-
September 2023First dosing of EDG-7500 moved the cardiovascular thesis from preclinical work into human testing.
-
April 2024CIRRUS-HCM began, creating the clinical data set that now underpins the lead program’s Phase 3 planning.
-
April 2025A $200.0 million gross follow-on offering strengthened liquidity before major trial expansion and strategic activity.
-
September 2025EDG-15400 entered Phase 1, adding a second clinical cardiovascular asset and reducing dependence on a single molecule at the platform level.
-
June–July 2026Positive 12-week EDG-7500 data were followed by completion of the Servier sale, leaving Edgewise better funded but strategically concentrated on cardiovascular development.
Edgewise’s advantage is not commercial scale but a targeted platform, lead clinical data, and unusual financing capacity. Its weakness is equally clear: value creation still depends on a small number of experimental assets.
Who are Edgewise’s main competitors, and what could differentiate it?
In HCM, Edgewise’s filings identify cardiac myosin inhibitor competition, including Bristol Myers Squibb’s CAMZYOS and Cytokinetics’ MYQORZO. Edgewise competes for clinical sites, patients, investigators, regulatory attention, and a differentiated label—not yet for sales.
What could become a durable advantage?
What limits the moat today?
Patents, compounds, know-how, and data can create barriers, but biotechnology moats are contingent. Rivals can win on efficacy, safety, convenience, monitoring, access, familiarity, or timing. Edgewise also relies on third parties for important trial and manufacturing activities. Its strongest current differentiator is the possibility of a favorable efficacy-and-safety profile; its weakest is the absence of confirmatory data and commercial infrastructure. A disciplined analysis should therefore separate scientific differentiation from a proven economic moat.
How financially strong is Edgewise after the transaction?
Financial strength improved dramatically, but the cash receipt must be adjusted for taxes, transaction costs, burn, and pivotal development. On a March 31, 2026 pro forma basis, Edgewise showed $1.532 billion of cash plus $466.4 million of marketable securities, for nearly $2.0 billion of liquid resources. Total assets were $2.014 billion, liabilities were $258.7 million, and stockholders’ equity was $1.755 billion. The balance sheet did not show funded debt in the pro forma presentation.
How should the balance sheet and burn be interpreted?
| Metric | Historical period | Pro forma after sale | Analytical meaning |
|---|---|---|---|
| Cash | $33.2M at March 31, 2026 | $1,532.4M | Reflects the upfront payment net of specified transaction adjustments. |
| Marketable securities | $466.4M at March 31, 2026 | $466.4M | Adds yield and liquidity while preserving capital for development. |
| Total assets | $518.5M at March 31, 2026 | $2,013.7M | The transaction transformed the scale of the balance sheet. |
| Total liabilities | $25.3M at March 31, 2026 | $258.7M | Pro forma liabilities include $225.9M of income taxes payable. |
| Operating cash used | $42.5M in Q1 2026 | Not separately projected | Historical burn is informative, but Phase 3 spending will reshape the rate. |
| FY2025 operating cash used | $143.8M | Not applicable | Provides an annual baseline before portfolio restructuring. |
Capital allocation is now the governance challenge. Management can accelerate retained programs, add assets, or preserve cash. The latest filings identified no dividend or repurchase program. The best use of cash is the portfolio that maximizes probability-adjusted value while preserving flexibility after delayed or negative data.
Who owns EWTX stock, and why does governance matter?
Edgewise has one common share class with one vote per share, aligning economic ownership and voting influence. The 2026 proxy statement reported concentrated ownership among specialist healthcare investors, large institutions, and insiders as of March 31, 2026. That base can support technically informed capital, while large holders can influence voting outcomes and liquidity.
Which holders have the greatest disclosed influence?
| Holder or group | Beneficial shares | Ownership | Why it matters |
|---|---|---|---|
| OrbiMed Advisors | 15,518,492 | 14.4% | Largest disclosed specialist holder and a major governance voice. |
| RA Capital Management | 10,428,437 | 9.7% | Concentrated life-sciences investor with substantial economic exposure. |
| Baker Bros. Advisors | 7,305,940 | 6.8% | Adds another experienced biotechnology capital provider. |
| Paradigm BioCapital | 6,541,210 | 6.1% | Meaningful influence among specialist shareholders. |
| BlackRock | 5,824,866 | 5.4% | Represents broad institutional ownership alongside specialists. |
| Novo Holdings | 5,549,900 | 5.2% | Strategic life-sciences capital with a multi-year perspective. |
| Directors and executive officers as a group | 24,818,347 | 21.3% | Creates substantial alignment, while requiring careful conflict oversight. |
How is the board structured?
Kevin Koch is president and chief executive officer, while Peter Thompson is board chair. Seven of nine directors were independent. The key issue is not dual-class control, but oversight of trials, business development, incentives, and a cash balance far larger than Edgewise’s prior operating scale.
Which risks, opportunities, and KPIs matter most for valuation?
A revenue multiple says little about a company with no product sales. A probability-adjusted model estimates patients, price, penetration, timing, costs, taxes, patent life, and approval odds, then adds net cash and contingent value.
How do operating risks flow into a DCF?
| Driver or risk | Current factual anchor | DCF effect | What would improve confidence? |
|---|---|---|---|
| Clinical probability | 53 patients completed 12 weeks in CIRRUS-HCM Part D | Changes probability-weighted future revenue | Controlled Phase 3 replication with consistent safety |
| Launch timing | Phase 3 initiation targeted for Q4 2026 | Delays reduce present value and extend burn | Trial start, enrollment pace, and regulatory clarity |
| Addressable market | HCM affects approximately 1 in 500 people, according to Edgewise | Sets the upper bound for treated-patient assumptions | Label breadth, diagnosis rates, and payer access |
| Cash runway | Nearly $2.0B of pro forma cash and securities at March 31, 2026 | Reduces near-term financing dilution and adds net cash | Disciplined burn and limited value-destructive deals |
| Competition | Existing and advanced HCM therapies establish a high benchmark | Affects penetration, price, and commercial expense | Differentiated efficacy, safety, monitoring, or label |
| Milestone value | Up to $1.10B is contingent under the Servier agreement | Should be probability-weighted, not counted at face value | Achievement of defined development, approval, and sales events |
| Concentration | EDG-7500 is the only retained asset with Phase 2 patient data | Raises asset-specific discounting and scenario dispersion | EDG-15400 proof-of-concept and broader pipeline maturity |
Opportunities include a broad HCM label, differentiated safety, EDG-15400 validation, and disciplined use of cash. Risks include clinical failure, safety findings, regulatory disagreement, competition, manufacturing dependence, intellectual-property challenges, delays, and capital misallocation. Discrete outcomes make scenario analysis more useful than a single forecast.
What is the key takeaway from Edgewise Therapeutics analysis?
Edgewise is no longer best described as a broadly diversified muscle-disease developer. It is a well-capitalized cardiovascular biotechnology company whose near- and medium-term story rests on EDG-7500, supported by earlier-stage EDG-15400 and EDG-003. The Servier sale converted sevasemten into $1.55 billion of upfront cash, up to $1.10 billion of contingent value, and a much lower direct expense base—but it also increased strategic concentration.
What supports the story is the combination of encouraging 12-week HCM data, a differentiated mechanistic thesis, and nearly $2.0 billion of pro forma liquidity at March 31, 2026. What could weaken it is failure to reproduce those signals in controlled Phase 3 trials, unexpected safety findings, a superior competitive profile elsewhere, or undisciplined deployment of the new cash. Students and investors should therefore monitor trial design, enrollment, systolic-function safety, KCCQ and NT-proBNP consistency, quarterly burn, EDG-15400 progression, Servier milestone realization, and board-level capital allocation. Edgewise has financial capacity for a pre-revenue biotech; durable value still depends on clinical execution, not the transaction gain.
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.